Bulgaria HIV Therapeutics Market Analysis Report [2022-30]

Bulgaria HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Bulgaria HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Huvepharma, Balkanpharma, and Sopharma. The market is driven by government policies, funding, and initiatives for the management of HIV infections in the country. The HIV therapeutics market in Bulgaria is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10BGPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Bulgaria AUTHOR: Dr. Vishwa Modhia

Buy Now

Bulgaria HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Bulgaria HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Bulgaria is in Southern Europe, on the Balkan Peninsula to the east. According to the most recent WHO data, HIV/AIDS-related deaths in Bulgaria reached 100 in 2020. Bulgaria ranks 134th in the world, with a death rate of 0.31 per 100,000 people. With 3300 HIV cases in 2020, the adult prevalence of HIV/AIDS in Bulgaria was less than 0.1 percent. Though the fight against HIV/AIDS in Bulgaria has had its ups and downs, the country has made significant progress in providing accessible treatment and diagnosis to its citizens over the last 20 years.

The Global Fund, an international organization supported by many private and public sector organizations, provided significant financial assistance to Bulgaria in its fight against AIDS, tuberculosis, and malaria. Even in the absence of Global Fund support, the fight against HIV/AIDS in Bulgaria is largely successful. The diagnosis rate is only 3.7 per 100,000 people, compared to the EU average of 5.4 per 100,000 people, making it an Eastern European success story. In 2019, Bulgaria spent 8.5 percent of its GDP on healthcare. The drug budget is $888 Mn, which is also the largest in Bulgaria.

Market Dynamics

Market Growth Drivers

The rate of new cases is also significantly higher in urban areas, with the capital city of Sofia alone accounting for 40% of all new cases. Although Sofia is home to 17.7 percent of Bulgaria's population, it has a much higher per capita rate than the rest of the country. Furthermore, according to WHO, many people simply will not or cannot access the treatment or testing they require due to stigma as well as limited access to resources and transportation. The experimenters attempted to avoid these factors by using private, at-home tests, and it was discovered that many people who would not have had access otherwise used the at-home option. Projects like this foreshadow a bright future in Bulgaria's fight against HIV/AIDS, leading to a better market for HIV therapeutics in the country.

Market Restraints

Some of the newer and more effective antiretroviral drugs for HIV treatment may not be available or accessible in Bulgaria due to high costs and limited funding previously provided by the Global Fund. In Bulgaria, there is a need for more HIV awareness and education, particularly among the general public and healthcare providers. These factors may deter new entrants from entering the Bulgaria HIV therapeutics market.

Competitive Landscape

Key Players

Sopharma (BGR)
Balkanpharma (BGR)
Huvepharma (BGR)
Gilead Sciences
AbbVie
Roche

Healthcare Regulations and Reimbursement Policies

The Bulgarian Drug Agency (BDA) is the regulatory body in charge of the approval and oversight of medicines, including HIV therapeutics, in Bulgaria. The BDA is in charge of evaluating and approving marketing authorization applications for medicines, as well as monitoring their safety and efficacy and enforcing regulatory compliance. The BDA is responsible for implementing EU regulations and guidelines for medicines in Bulgaria and reports to the Ministry of Health.

The Bulgarian National Health Insurance Fund covered antiretroviral therapy (ART) for HIV treatment (NHIF). The National Health Insurance Fund (NHIF) is in charge of administering Bulgaria's national health insurance program and covers the cost of HIV therapeutics, including ART, for eligible patients. HIV therapeutics are reimbursed in Bulgaria based on certain criteria, such as the patient's disease stage, the type of antiretroviral drugs prescribed, and the treatment guidelines established by the Bulgarian Ministry of Health.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.